Alnylam Pharmaceuticals (ALNY) Long-Term Debt Repayments (2025)
Alnylam Pharmaceuticals' (ALNY) quarterly Long-Term Debt Repayments came in at $52.3 million in Q4 2025, down 95.29% quarter-over-quarter from $1.1 billion in Q3 2025.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Long-Term Debt Repayments (2025) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has reported Long-Term Debt Repayments for 1 consecutive years, with $52.3 million the latest figure, recorded in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.33 Bn | 198.34 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.55 Bn | 177.37 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.28 Bn | 124.42 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.90 Bn | 73.91 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.14 Bn | 55.96 Bn | 1.37 Bn | - |
| 6 | Moderna | 55.12 Bn | 49.98 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.85 Bn | 30.54 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.21 Bn | 29.93 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.89 Bn | 29.89 Bn | 1.16 Mn | - |
| 10 | Insmed | 27.14 Bn | 25.98 Bn | 358.27 Mn | - |